NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NRG Oncology
Thomas Jefferson University
Wake Forest University Health Sciences
University of Nebraska
Radiation Therapy Oncology Group
University of California, Davis
Radiation Therapy Oncology Group
Institut Cancerologie de l'Ouest
Mayo Clinic
Abramson Cancer Center at Penn Medicine
Radiation Therapy Oncology Group
Institut de Cancérologie de Lorraine